Evidence map›Paper›PMID 41132987›Full record

ArticleTranslational lung cancer research2025

Radiomic phenotypes of oligometastatic non-small cell lung cancer.

Kevin M Boehm, Emily S Lebow, N Ari Wijetunga, Justin Haseltine, Andreas Rimner, Narek Shaverdian, Helena Yu, Bob T Li, James M Isbell, Rosna Mirtcheva-Trocheva and 2 more

Abstract read
In one paragraph

Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kevin M BoehmDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Emily S LebowDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
N Ari WijetungaDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Justin HaseltineDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andreas RimnerDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Narek ShaverdianDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Helena YuDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Bob T LiDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
James M IsbellDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rosna Mirtcheva-TrochevaDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Puneeth IyengarDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Daniel R GomezDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Background: Identifying biomarkers that optimize patient selection for ablative therapy in metastatic non-small cell lung cancer (NSCLC) remains an unmet need. In this study, we identified radiomic features associated with sustained oligometastatic and indolent NSCLC. Methods: We curated a retrospective cohort of 167 patients (132 training/validation, 35 test) with treatment-naïve, metastatic NSCLC and pre-treatment positron emission tomography/computed tomography (PET/CT). We extracted radiomic features from the primary lesion and used Pearson's correlation to identify those associated with extent of metastatic disease. For a subset (n=83), we also identified features associated with overall survival (OS) using Cox proportional hazards models. Results: We found that the inverse flatness was lower (r=-0.23; q=0.04) and surface area-to-volume ratio (SVR) was higher (r=0.24; q=0.04) in primary lesions for cases with more metastases. We further found that higher gray level variance on CT portends shorter OS [hazard ratio (HR) =1.84, 95% confidence interval (CI): 1.32-2.56, q=0.004; test c=0.74, 95% CI: 0.52-0.90]. Risk groups derived from these scores exhibited median survival times in the training set of 12.6 and >50 months (P=0.001) and in the test set of 13.8 and 32.7 months (P=0.06). This feature was determined primarily by inclusion of low-intensity voxels. Conclusions: This study identifies radiomic features of indolent NSCLC, demonstrating that flatter, higher surface area primary disease is associated with a greater number of metastases, and primary lesions with lower density representing lung parenchyma, airspace, or lower-density tumor portend shorter OS. These findings lay the groundwork toward identifying patients suitable for ablative radiotherapy despite the presence of metastatic disease.

Indexed as

non-small cell lung cancer (NSCLC)Oligometastaticradiomics

Identifiers

PMID41132987
PMCPMC12541869

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.